Compass Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $850 | $0 | $2,844 | $0 |
Gross Profit | -463 | 2,376 | -466 | |
EBITDA | -12,307 | -14,925 | -11,460 | |
EBIT | -12,770 | -15,393 | -11,926 | |
Net Income | -13,076 | -10,787 | -13,415 | -9,964 |
Net Change In Cash | 850 | 0 | 2,844 | 0 |
Free Cash Flow | -10,754 | -13,888 | -12,363 | -5,932 |
Cash | 19,404 | 23,674 | 24,228 | 30,426 |
Basic Shares | 137,589 | 136,608 | 127,668 | 127,424 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,890 | -1,904 | -1,624 | -2,404 |
EBITDA | -48,473 | -37,391 | -29,611 | -25,320 |
EBIT | -50,363 | -39,295 | -31,235 | -27,724 |
Net Income | -42,494 | -36,795 | -82,551 | -29,500 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -109,568 | 97,175 | 21,773 | |
Free Cash Flow | -40,648 | -34,337 | -21,234 | -26,909 |
Cash | 24,228 | 34,946 | 144,514 | 47,076 |
Basic Shares | 127,027 | 105,186 | 62,870 | 30,776 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.10 |
2024-03-31 | -$0.08 |
2023-12-31 | -$0.11 |
2023-09-30 | -$0.08 |
